Madrigal Pharmaceuticals Inc. is a pharmaceutical company based in the United States, specializing in developing and commercializing therapeutic treatments for cardiovascular-metabolic diseases and NASH. With an ESG risk rating score of 26.2, the company is categorized as a medium-risk investment. Their product portfolio includes MGL-3196, a liver-directed THR agonist beneficial for treating non-alcoholic steatohepatitis and familial hypercholesterolemia. MGL-3196 also aids in lowering triglycerides and has anti-diabetic properties.